中国药物与临床
中國藥物與臨床
중국약물여림상
CHINESE REMEDIES & CLINICS
2014年
8期
1022-1025
,共4页
陈小波%龚央央%王华富%潘晨
陳小波%龔央央%王華富%潘晨
진소파%공앙앙%왕화부%반신
阿奇霉素%序贯疗法%社区获得性肺炎%荟萃分析
阿奇黴素%序貫療法%社區穫得性肺炎%薈萃分析
아기매소%서관요법%사구획득성폐염%회췌분석
Azithromycin%Consecutive therapy%Communityacquired pneumonia%Metaanalysis
目的:比较阿奇霉素序贯疗法与常规治疗社区获得性肺炎(CAP)的疗效和安全性。方法检索万方数据库“WANFANGDATA”和中国知网数据库(CNKI),查找关于阿奇霉素序贯治疗(研究组)和常规静脉滴注治疗(对照组)CAP的随机对照研究。采用Meta分析方法分析阿奇霉素序贯疗法与常规治疗CAP的临床疗效、不良反应和静脉滴注时间。结果共纳入7项研究。结果显示研究组和对照组的临床总有效率差异无统计学意义(Z=1.03,P=0.30,OR=1.36,95%CI 0.76~2.43);2组不良反应发生率(Z=5.19,P<0.01,OR=0.37,95%CI 0.26~0.54)和静脉滴注时间(Z=36.84,P<0.01,WMD=-6.52,95%CI-6.87~-6.18)比较差异有统计学意义。Begg′s检验和Egger′s检验显示无发表性偏倚。结论阿奇霉素序贯疗法治疗CAP安全有效。
目的:比較阿奇黴素序貫療法與常規治療社區穫得性肺炎(CAP)的療效和安全性。方法檢索萬方數據庫“WANFANGDATA”和中國知網數據庫(CNKI),查找關于阿奇黴素序貫治療(研究組)和常規靜脈滴註治療(對照組)CAP的隨機對照研究。採用Meta分析方法分析阿奇黴素序貫療法與常規治療CAP的臨床療效、不良反應和靜脈滴註時間。結果共納入7項研究。結果顯示研究組和對照組的臨床總有效率差異無統計學意義(Z=1.03,P=0.30,OR=1.36,95%CI 0.76~2.43);2組不良反應髮生率(Z=5.19,P<0.01,OR=0.37,95%CI 0.26~0.54)和靜脈滴註時間(Z=36.84,P<0.01,WMD=-6.52,95%CI-6.87~-6.18)比較差異有統計學意義。Begg′s檢驗和Egger′s檢驗顯示無髮錶性偏倚。結論阿奇黴素序貫療法治療CAP安全有效。
목적:비교아기매소서관요법여상규치료사구획득성폐염(CAP)적료효화안전성。방법검색만방수거고“WANFANGDATA”화중국지망수거고(CNKI),사조관우아기매소서관치료(연구조)화상규정맥적주치료(대조조)CAP적수궤대조연구。채용Meta분석방법분석아기매소서관요법여상규치료CAP적림상료효、불량반응화정맥적주시간。결과공납입7항연구。결과현시연구조화대조조적림상총유효솔차이무통계학의의(Z=1.03,P=0.30,OR=1.36,95%CI 0.76~2.43);2조불량반응발생솔(Z=5.19,P<0.01,OR=0.37,95%CI 0.26~0.54)화정맥적주시간(Z=36.84,P<0.01,WMD=-6.52,95%CI-6.87~-6.18)비교차이유통계학의의。Begg′s검험화Egger′s검험현시무발표성편의。결론아기매소서관요법치료CAP안전유효。
Objective To compare the efficacy and safety of azithromycin consecutive and conventional therapy for the treatment for community-acquired pneumonia (CAP). Methods The randomized controlled trials regarding azithromycin consecutive (research group) and conventional intravenous therapy (control group) on CAP were searched from WANFANG data and CNKI. And the efficacy, adverse reaction and duration of intravenous drip were evaluated by meta-analysis. Results Seven RCTs were included in this study. There was no significant difference in the total effective rate (Z=1.03, P=0.30, OR=1.36, 95% CI 0.76-2.43), whereas the differences in the incidence of adverse events (Z=5.19, P<0.01, OR=0.37, 95% CI 0.26-0.54) and the duration of intravenous drip (Z=36.84, P<0.01, WMD=-6.52, 95%CI-6.87~-6.18) were statistically significant. There was nil publication bias as analyzed by Begg′s test and Egger′s test. Conclusion Azithromycin consecutive therapy for CAP is safe and effective.